| Identification | Back Directory | [Name]
AP-5 LITHIUM SALT | [CAS]
125229-62-1 | [Synonyms]
AP-5 LITHIUM SALT
DL-2-AMINO-5-PHOSPHONOVALERIC ACIDLITHIU M
DL-2-Amino-5-phosphonopentanoic acid, AP-5
DL-2-AMINO-5-PHOSPHONOVALERIC ACID LITHIUM SALT
DL-2-AMINO-5-PHOSPHONOPENTANOIC ACID LITHIUM SALT
DL-2-AMino-5-phosphonovaleric acid lithiuM salt ~95% | [Molecular Formula]
C5H11LiNO5P | [MDL Number]
MFCD00078901 | [MOL File]
125229-62-1.mol | [Molecular Weight]
203.06 |
| Hazard Information | Back Directory | [Uses]
DL-AP5 (2-APV) lithium is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 lithium shows significantly antinociceptive activity. DL-AP5 lithium specifically blocks on channels in the rabbit retina[1][2][3]. | [Biological Activity]
DL-2-Amino-5-phosphonovaleric acid is a selective N-methyl-d-aspartate (NMDA) receptor antagonist used frequently in studies of neurological processes''Anticonvulsant; potent and selective antagonist for NMDA receptors. | [in vivo]
DL-AP5 (0-10 μg/rat, Intra-CA1) significantly decreases the effect of NMDA[3].
DL-AP5 (0-10 nmol, Intracerebroventricular injection) causes a dose-dependent increase in food consumption[4].
DL-AP5 (5 nmol, Intracerebroventricular injection) attenuates the decreased food consumption induced by the intracerebroventricular injection of ghrelin[4]. | Animal Model: | Male Wistar rats (180-230 g)[3] | | Dosage: | 1, 3.2 and 10 μg/rat | | Administration: | Injected into the intra-dorsal hippocampal (intra-CA1) immediately after shock administration, once | | Result: | Significantly decreased the effect of NMDA (10-2 μg/rat, intra-CA1) with significant interaction. |
| Animal Model: | Broilers cockerels (3-h fooddeprived (FD3), n=8 for each group)[4] | | Dosage: | 0, 2.5, 5, and 10 nmol; in a volume of 10 μL | | Administration: | Intracerebroventricular injection | | Result: | Caused a dose-dependent increase in food consumption which was significant for 5 and 10 nmol doses. |
| Animal Model: | Broilers cockerels (3-h fooddeprived (FD3), n=8 for each group)[4] | | Dosage: | 5 nmol | | Administration: | Intracerebroventricular injection, followed by ghrelin (0.6 nmol) | | Result: | Attenuated the decreased food consumption induced by the intracerebroventricular injection of ghrelin. |
| [IC 50]
NMDA Receptor | [References]
[1] Murray CW, et al. Neurokinin and NMDA antagonists (but not a kainic acid antagonist) are antinociceptive in the mouse formalin model. Pain. 1991;44(2):179-185. DOI:10.1016/0304-3959(91)90135-K
[2] Massey SC, et al. N-methyl-D-aspartate receptors of ganglion cells in rabbit retina. J Neurophysiol. 1990;63(1):16-30. DOI:10.1152/jn.1990.63.1.16
[3] Jafari-Sabet M. NMDA receptor blockers prevents the facilitatory effects of post-training intra-dorsal hippocampal NMDA and physostigmine on memory retention of passive avoidance learning in rats. Behav Brain Res. 2006 Apr 25;169(1):120-7. DOI:10.1016/j.bbr.2005.12.011
[4] Taati M, et al. The effects of DL-AP5 and glutamate on ghrelin-induced feeding behavior in 3-h food-deprived broiler cockerels. J Physiol Biochem. 2011 Jun;67(2):217-23. DOI:10.1007/s13105-010-0066-y
[5] Chen T, et al. Glutamate-induced rapid induction of Arc/Arg3.1 requires NMDA receptor-mediated phosphorylation of ERK and CREB. Neurosci Lett. 2017 Nov 20;661:23-28. DOI:10.1016/j.neulet.2017.09.024 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
SIGMA-RBI
|
| Tel: |
800 736 3690 (Orders) |
| Website: |
www.sigma-aldrich.com |
| Company Name: |
CHEMICAL LAND21
|
| Tel: |
82- 2 -783 - 8063 |
| Website: |
www.chemicalland21.com |
|